The delay in marketing the product in Australia lies to a degree with the TGA. New Australian laws giving the TGA regulatory oversight of manufacturing and clinical use of autologous stem cells and tissues were only announced in October and come into effect early next year. This is after some years of talking about it and industry consultation
IMO
Ann: Avita Medical Annual General Meeting Presentation, page-7
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
0.020(0.78%) |
Mkt cap ! $180.1M | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.63 | $2.56 | $229.1K | 88.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $2.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.60 | 18050 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| AVH (ASX) Chart |